AR117573A1 - Formas cristalinas de un inhibidor tlr7 / tlr8 - Google Patents
Formas cristalinas de un inhibidor tlr7 / tlr8Info
- Publication number
- AR117573A1 AR117573A1 ARP190101308A ARP190101308A AR117573A1 AR 117573 A1 AR117573 A1 AR 117573A1 AR P190101308 A ARP190101308 A AR P190101308A AR P190101308 A ARP190101308 A AR P190101308A AR 117573 A1 AR117573 A1 AR 117573A1
- Authority
- AR
- Argentina
- Prior art keywords
- tlr7
- crystalline forms
- tlr8 inhibitor
- tlr8
- inhibitor
- Prior art date
Links
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 title 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 title 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 title 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- OXDQXRVWDYGAHX-SAVAPUMLSA-N (3S)-N-[4-[[5-(1,6-dimethylpyrazolo[3,4-b]pyridin-4-yl)-3-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridin-1-yl]methyl]-1-bicyclo[2.2.2]octanyl]morpholine-3-carboxamide Chemical compound CN1N=CC=2C1=NC(=CC=2N1CC2=C(CC1)N(N=C2C)CC12CCC(CC1)(CC2)NC(=O)[C@H]1NCCOC1)C OXDQXRVWDYGAHX-SAVAPUMLSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Una forma cristalina del compuesto (S)-N-(4-((5-(1,6-dimetil-1H-pirazolo[3,4-b]piridin-4-il)-3-metil-4,5,6,7-tetrahidro-1H-pirazolo[4,3-c]piridin-1-il)metil)biciclo[2.2.2]octan-1-il)morfolina-3-carboxamida en su forma libre. Reivindicación 2: La forma cristalina de acuerdo con la reivindicación 1, que comprende la Forma A. Reivindicación 10: La forma cristalina de acuerdo con la reivindicación 9, que comprende la Forma HA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018087448 | 2018-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117573A1 true AR117573A1 (es) | 2021-08-18 |
Family
ID=67145832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101308A AR117573A1 (es) | 2018-05-18 | 2019-05-16 | Formas cristalinas de un inhibidor tlr7 / tlr8 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12084460B2 (es) |
| EP (1) | EP3793998A1 (es) |
| JP (2) | JP7407740B2 (es) |
| KR (1) | KR20210013554A (es) |
| CN (1) | CN112119078A (es) |
| AR (1) | AR117573A1 (es) |
| AU (1) | AU2019268583B2 (es) |
| BR (1) | BR112020022738A2 (es) |
| CA (1) | CA3097312A1 (es) |
| CL (1) | CL2020002967A1 (es) |
| MX (2) | MX2020012259A (es) |
| TW (2) | TWI826446B (es) |
| WO (1) | WO2019220390A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
| EP3807270B1 (en) | 2018-06-12 | 2023-09-13 | F. Hoffmann-La Roche AG | Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| US11952363B2 (en) | 2018-07-23 | 2024-04-09 | Hoffmann-La Roche Inc. | Piperazine compounds for the treatment of autoimmune disease |
| CN112638908A (zh) | 2018-09-04 | 2021-04-09 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的苯并噻唑类化合物 |
| CN112654618A (zh) | 2018-09-06 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的新型环脒化合物 |
| EP4182032A1 (en) | 2020-07-14 | 2023-05-24 | F. Hoffmann-La Roche AG | Hydroisoquinoline or hydronaphthyridine compounds for the treatment of autoimmune disease |
| US11661431B2 (en) | 2021-04-16 | 2023-05-30 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| EP4398989A1 (en) | 2021-09-10 | 2024-07-17 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| EP4405051A1 (en) | 2021-09-24 | 2024-07-31 | F. Hoffmann-La Roche AG | Pyrazolo[3,4-b]pyridine compounds for the treatment of autoimmune disease |
| CA3242349A1 (en) * | 2022-01-11 | 2023-07-20 | Novartis Ag | Tlr7/8-antagonist for treating sjogren's syndrome or mixed connective tissue disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2222545A1 (en) | 1995-06-07 | 1996-12-19 | Sugen, Inc. | Quinazolines and pharmaceutical compositions |
| CA2619462A1 (en) | 2005-08-16 | 2007-02-22 | Amgen, Inc. | Phosphodiesterase 10 inhibitors |
| ES2637113T3 (es) | 2011-01-10 | 2017-10-10 | Infinity Pharmaceuticals, Inc. | Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas |
| BR112014019699B1 (pt) | 2012-02-08 | 2021-12-07 | Janssen Sciences Ireland Uc | Derivados de piperidino-pirimidina, seu uso no tratamento de infecções virais e composição farmacêutica que os compreende |
| MD4659B1 (ro) | 2013-07-30 | 2019-11-30 | Gilead Connecticut Inc | Polimorf al inhibitorilor SYK |
| WO2017032289A1 (en) | 2015-08-25 | 2017-03-02 | Beigene, Ltd. | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
| US10954233B2 (en) | 2016-09-09 | 2021-03-23 | Novartis Ag | Compounds and compositions as inhibitors of endosomal toll-like receptors |
-
2019
- 2019-05-16 EP EP19735624.9A patent/EP3793998A1/en active Pending
- 2019-05-16 CA CA3097312A patent/CA3097312A1/en active Pending
- 2019-05-16 WO PCT/IB2019/054066 patent/WO2019220390A1/en active Application Filing
- 2019-05-16 US US17/056,351 patent/US12084460B2/en active Active
- 2019-05-16 AU AU2019268583A patent/AU2019268583B2/en active Active
- 2019-05-16 BR BR112020022738-2A patent/BR112020022738A2/pt unknown
- 2019-05-16 KR KR1020207032942A patent/KR20210013554A/ko not_active Application Discontinuation
- 2019-05-16 JP JP2020564243A patent/JP7407740B2/ja active Active
- 2019-05-16 AR ARP190101308A patent/AR117573A1/es unknown
- 2019-05-16 TW TW108116864A patent/TWI826446B/zh active
- 2019-05-16 MX MX2020012259A patent/MX2020012259A/es unknown
- 2019-05-16 TW TW112150642A patent/TW202417000A/zh unknown
- 2019-05-16 CN CN201980032642.0A patent/CN112119078A/zh active Pending
-
2020
- 2020-11-13 MX MX2023013584A patent/MX2023013584A/es unknown
- 2020-11-16 CL CL2020002967A patent/CL2020002967A1/es unknown
-
2023
- 2023-12-18 JP JP2023212606A patent/JP2024037930A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024037930A (ja) | 2024-03-19 |
| BR112020022738A2 (pt) | 2021-02-02 |
| US20210206783A1 (en) | 2021-07-08 |
| AU2019268583A1 (en) | 2020-10-29 |
| EP3793998A1 (en) | 2021-03-24 |
| MX2023013584A (es) | 2023-11-30 |
| JP7407740B2 (ja) | 2024-01-04 |
| AU2019268583B2 (en) | 2022-01-27 |
| CA3097312A1 (en) | 2019-11-21 |
| TWI826446B (zh) | 2023-12-21 |
| JP2021523918A (ja) | 2021-09-09 |
| KR20210013554A (ko) | 2021-02-04 |
| MX2020012259A (es) | 2021-01-29 |
| TW202417000A (zh) | 2024-05-01 |
| TW202015698A (zh) | 2020-05-01 |
| WO2019220390A1 (en) | 2019-11-21 |
| US12084460B2 (en) | 2024-09-10 |
| CL2020002967A1 (es) | 2021-04-30 |
| CN112119078A (zh) | 2020-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR117573A1 (es) | Formas cristalinas de un inhibidor tlr7 / tlr8 | |
| CO2017005790A2 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
| CL2017001617A1 (es) | Formas sólidas de un inhibidor ask1 referencia cruzada a aplicaciones relacionadas | |
| UY38448A (es) | Compuestos de azol-amida pesticidamente activos | |
| CL2015002304A1 (es) | Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato | |
| DOP2021000038A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| AR106192A1 (es) | Formas cristalinas de un agente antiviral contra la hepatitis b | |
| AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
| AR102977A1 (es) | Inhibidores de erk | |
| CR20120277A (es) | Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa | |
| NI201200146A (es) | Inhibidores no nucleosídicos de la transcriptasa inversa | |
| CL2009000275A1 (es) | Compuestos derivados de furo [3,2-c]piridina y tieno [3,2-c] piridina; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| MX2018010025A (es) | Derivados de quinazolindion-6-carbonilo y su utilizacion como herbicidas. | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| PE20180035A1 (es) | Tableta de ribociclib | |
| NI201100069A (es) | Inhibidores de la integrasa del vih. | |
| CL2016000695A1 (es) | Un inhibidor selectivo de la fosfatidilinositol 3-quinasa-gamma | |
| AR103350A1 (es) | Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas | |
| CR20150555A (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina | |
| GB2542515A (en) | Systems, methods, and kits for cleansing an ocular region | |
| CL2016000496A1 (es) | Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias. | |
| CL2021000904A1 (es) | Método para convertir las formas e, f y g cristalinas de la sal de bis-bromuro de hidrógeno de (s)-n-((5-(etilsulfonil)piridin-2-il)metil)-7-isopropil-6-((trans-4-(trifluorometil) ciclohexil) metil)-6,7-dihidro-5h-pirrolo[3,4-b]piridin-3-carboxamida en la forma d cristalina de la sal de bis-bromuro de hidrógeno. solicitud divisional de la solicitud 190-2020 | |
| MX2016013265A (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| UY35036A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| AR104241A1 (es) | Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos |